UK Markets close in 3 hrs 49 mins

Targovax ASA (0RIS.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
0.7500-0.2520 (-25.15%)
As of 05:58PM GMT. Market open.

Targovax ASA

Vollsveien 19
Lysaker 1366
47 21 39 88 10

Full-time employees19

Key executives

NameTitlePayExercisedYear born
Dr. Erik Digman WiklundChief Exec. Officer2.8MN/AN/A
Dr. Victor Levitsky M.D., Ph.D.Chief Scientific Officer3.09MN/AN/A
Dr. Ingunn Munch LindvigVP & Head of Regulatory Affairs1.86MN/AN/A
Dr. Lone Ottesen M.D., Ph.D.Chief Medical Officer3.35MN/AN/A
Mr. Ola MelinVP & Head of Manufacturing1.61MN/AN/A
Dr. Lubor Gaal Ph.D.Chief Financial OfficerN/AN/A1968
Mr. Jon Amund Eriksen M.Sc., MScSpecial AdvisorN/AN/AN/A
Prof. Gustav Gaudernack Ph.D.Chief Scientific AdviserN/AN/AN/A
Dr. Thomas Birkballe HansenVP & Head of ResearchN/AN/AN/A
Dr. Peter Skorpil Ph.D.VP of Bus. Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.


Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.

Corporate governance

Targovax ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.